PMGC Holdings (ELAB) Interest & Investment Income (2022 - 2026)
PMGC Holdings (ELAB) posted Interest & Investment Income of $62921.0 for Q1 2026, up 122.8% sequentially from $28241.0 in Q4 2025.
PMGC Holdings (ELAB) Interest & Investment Income (2022 - 2026) Analysis & Trends
PMGC Holdings has reported Interest & Investment Income for 5 years, with the latest figure at $62921.0 in Q1 2026.
- Quarterly Interest & Investment Income changed N/A year-over-year to $62921.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $128214.0 (changed N/A YoY) and the FY2025 annual result came in at $118030.0, up 815.6% from the prior year.
- Interest & Investment Income climbed to $62921.0 in Q1 2026 per ELAB's latest filing, from $28241.0 in the prior quarter.
- Over five years, Interest & Investment Income peaked at $3.2 million in Q3 2022 and troughed at -$3.2 million in Q4 2022.
- A 5-year average of $4286.5 and a median of $349.0 in 2023 frame the typical range for Interest & Investment Income.
- The sharpest annual moves came in 2023 and 2025: Interest & Investment Income slumped 100.0% in 2023, then jumped 25590.53% in 2025.
- Over 5 years, Interest & Investment Income stood at -$3.2 million in 2022, then surged by 100.0% to $83.0 in 2023, then surged by 15136.14% to $12646.0 in 2024, then surged by 123.32% to $28241.0 in 2025, then surged by 122.8% to $62921.0 in 2026.
- According to Business Quant data, Interest & Investment Income over the past three periods registered $62921.0, $28241.0, and $24406.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 120.60 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -48.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 48.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 67.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 27.90 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 28.14 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 115.94 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 10.98 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 5.13 Mn |
| 10 | PMGC Holdings | 31.22 Mn | 12.43 Mn | 385,691.00 | 83,159.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 62,921.00 |
| Dec 31, 2025 | 28,241.00 |
| Sep 30, 2025 | 24,406.00 |
| Dec 31, 2024 | 12,646.00 |
| Sep 30, 2024 | 95.00 |
| Jun 30, 2024 | 64.00 |
| Mar 31, 2024 | 86.00 |
| Dec 31, 2023 | 83.00 |
| Sep 30, 2023 | 25.00 |
| Jun 30, 2023 | 349.00 |
| Mar 31, 2023 | 5,107.00 |
| Dec 31, 2022 | -3.24 Mn |
| Sep 30, 2022 | 3.16 Mn |